Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)
| Autor: | Theo Ruers, Cornelis J. A. Punt, Frits van Coevorden, Jean-Pierre Pierie, Inne Borel Rinkes, Jonathan A. Ledermann, Graeme John Poston, Wolf O. Bechstein, Marie-Ange Lentz, Murielle E. Mauer, Eric Van Cutsem, Manfred P. Lutz, Bernard Nordlinger |
|---|---|
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 33:3501-3501 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2015.33.15_suppl.3501 |
| Popis: | 3501 Background: This study evaluates the benefit of combining systemic chemotherapy (CT) with local tumor destruction by RFA in patients with unresectable CRC LM up to 9 lesions and without extrahepatic disease. Overall survival (OS) at 30 months and progression free survival (PFS) results were reported (Ann Oncol. 23(10): 2619-26, 2012). We now report on OS results, after a long term median follow-up of 9.7 years. Methods: Between 2002 and 2007, 119 pts were randomized between CT alone (59) or RFA+CT (60). In both arms, CT consisted of 6 months FOLFOX (oxaliplatin 85mg/m2 and LV5FU2) plus, since October 2005, bevacizumab. In the CT arm resection was allowed when unresectable disease was converted by CT to resectable disease. Primary objective was a 30-months OS rate > 38% for the combined treatment group. OS and PFS were secondary endpoints. Results: In the RFA+CT arm, 56 pts (93.3%) received RFA which was combined with resection in 27 pts (45%), 1 pt had all metastases resected (ineligible), 2 pts were... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|